Last reviewed · How we verify
renal cell carcinoma rcc
Approved treatments
Clinical guidelines
- FDA label — 2L
Adult patients with advanced RCC who have received prior anti-angiogenic therapy. - FDA label — 1L
Adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. - FDA label — 1L
Adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- renal cell carcinoma rcc patent landscape — cliff calendar, originator estates, attackable patents
- renal cell carcinoma rcc treatment landscape brief
- renal cell carcinoma rcc treatment updates RSS
Frequently asked questions about renal cell carcinoma rcc
What are the treatment guidelines for renal cell carcinoma rcc?
FDA label publishes guidelines for renal cell carcinoma rcc. 3 guideline references tracked.
Related
- Treatment landscape: renal cell carcinoma rcc patent cliff · renal cell carcinoma rcc CI report
- All diseases: Browse the disease index · Disease landscape hub